Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase III trial for Fortical approved in U.K.

June 28, 1996

PEG-hemoglobin undergoes trial

June 28, 1996

Potential photodynamic therapy described

June 28, 1996

Pharmacyclic's Gd-Tex enhances radiation therapy

June 28, 1996

Pan-agonist retinoid described by Ligand

June 28, 1996

Antineoplastic/antifungal agent revealed

June 28, 1996

MT-332: Pharma Mar's novel cytotoxic metabolite

June 28, 1996

Antitumor epidioxymanadic acid described by Pharma Mar

June 28, 1996

Virulizin undergoes phase I/II in pancreatic cancer

June 28, 1996

Marimastat enters U.S. and U.K. phase III trial

June 28, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 4, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...